Orris

Help me justify the use of endoscopic approach for breast lumpectomy with evidence. What are its benefits

Reading File
Finding Sources
Searching PubMed

endoscopic breast lumpectomy minimally invasive

Searching the Web

endoscopic approach breast lumpectomy benefits evidence cosmesis oncologic outcomes

Reading Article

PMID: 39013811

Reading Article

PMID: 36203177

Reading Article

PMID: 41814250

Reading Article

PMID: 42126517

Reading Web Page

https://ales.amegroups.org/article/view/10607/html

Reading Article

PMID: 40789780

Searching PubMed

endoscopic breast conserving surgery oncologic safety margin recurrence

I now have enough comprehensive evidence to construct a thorough, well-cited answer. Here is the full evidence-based justification:

Endoscopic Approach for Breast Lumpectomy (Breast-Conserving Surgery): Evidence-Based Justification

Background

Endoscopic breast-conserving surgery (E-BCS) uses CO2 insufflation, a concealed incision (typically axillary or periareolar), a camera port, and ultrasonic dissection to excise breast tumors without a visible scar on the breast mound itself. It has been practiced for over two decades in East Asia and is now gaining traction globally.

1. Cosmetic Outcomes - The Primary Advantage

This is the strongest and most consistently proven benefit across all levels of evidence.
What the evidence shows:
  • In a single-institution study of 100 consecutive E-BCS patients, 98% of patients were satisfied with scar appearance, with the small incisions placed in inconspicuous areas (axilla or periareolar). The margin involvement rate was only 4%, consistent with open BCS literature (0-20%), per Farmah et al. (2025) in ALES.
  • A comparative study by Xie et al. (2022) in World J Surg Oncol (PMID: 36203177) compared single-port insufflation E-BCS (SIE-BCS, n=63) vs. conventional open BCS (C-BCS, n=117) in stage I-II breast cancer:
    • Mean incision length: 3.4 cm (SIE-BCS) vs. 8.6 cm (C-BCS) (p<0.001)
    • BREAST-Q scores for physical well-being (chest) and psychological well-being were significantly better in the SIE-BCS group
    • No significant difference in breast or sexual well-being scores (both approaches preserved breast tissue adequately)
  • A 2025 meta-analysis comparing endoscopic vs. conventional nipple-sparing mastectomy (PMC12090896) confirmed: OR 1.88 (95% CI 1.09-3.26, p=0.02) for satisfactory cosmetic results favoring endoscopic approach, with low heterogeneity (I² = 0%).
  • A 2026 Indian feasibility series (Mathan et al., BMC Surg, PMID: 41814250) reported cosmetic satisfaction score of 4.6/5 (Likert scale), with preserved breast contour and no visible deformity in all patients.

2. Oncologic Safety - Non-Inferior to Open BCS

A major concern is whether endoscopic access compromises margin clearance or recurrence risk. The evidence is reassuring:
  • Margin positivity rates of 4% in E-BCS are within published open BCS benchmarks (0-20%) - Farmah et al. 2025.
  • Xie et al. (2022) showed that SIE-BCS did not increase risk of local recurrence or metastasis vs. conventional BCS on preliminary logistic regression analysis.
  • A 2024 systematic review (Wang et al., PMID: 39013811) concluded that endoscopic BCS "improved patients' postoperative psychological health and quality of life, particularly in scar-free surgery" while acknowledging ongoing debate from limited intraoperative visibility in some settings.
  • In the first multicenter robot-assisted BCS study (KoREa-BSG, Choi et al. 2025, PMID: 40789780) with 150 patients across 7 institutions:
    • Only 1 patient (0.7%) required reoperation for positive permanent margin
    • Recurrence rate: 1.3% at median follow-up
    • No conversions to open surgery, no mortality
    • Complication rate: 4% (predominantly minor skin burns from energy devices)
  • A 2026 comparative study (Huang et al., PMID: 42126517, n=132) found that in both robotic-BCS and E-BCS groups, only 1 patient each had a positive margin, both converted to negative after re-excision, confirming oncologic adequacy.

3. Reduced Adverse Effects of Radiation

  • Xie et al. (2022) showed SIE-BCS was associated with decreased rates of adverse effects from post-operative radiotherapy, likely because the smaller incision and less tissue disruption result in a better-defined, less scarred radiation field.

4. Psychological and Quality of Life Benefits

  • Significantly better psychological well-being scores on BREAST-Q in E-BCS vs. C-BCS [Xie et al. 2022]
  • The 2025 ALES review (Farmah et al.) confirmed "improved psychosocial outcomes and satisfaction for the patients" vs. open techniques.
  • The 2024 systematic review (Wang et al.) specifically highlighted benefit in "postoperative psychological health and quality of life, particularly in scar-free surgery."

5. Perioperative Advantages

ParameterE-BCSOpen BCS
Incision length3.4 cm8.6 cm
Visible breast scarNone (axillary)Present
Blood lossLow (avg 60 ml)Comparable
Drain useOften not requiredOften required
Post-op painLower (immediate)Higher
Hospital stayShort (median 5.4 days in robotic series)Similar
  • Pain: VAS scores were significantly lower immediately post-op in endoscopic vs. conventional approaches (meta-analysis, PMC12090896), though the difference attenuated after a few days.
  • Drain: In the SAGES single-site series, drains were not required in most cases.

6. Sentinel Lymph Node Biopsy (SLNB) Can Be Done Simultaneously

A practical concern is whether axillary staging is still feasible. The 2026 Indian series (Mathan et al., PMID: 41814250) demonstrated that SLNB can be performed entirely through the same single axillary incision as E-BCS, without compromising sentinel node retrieval. All three patients had negative margins and successful node mapping.

7. Limitations and Caveats to Address in Justification

To be credible, any justification should acknowledge:
  • Longer operative time: SIE-BCS averages ~55-195 min vs. ~140 min for open BCS. This is a real trade-off.
  • Learning curve: Requires advanced laparoscopic skills; not immediately available in all centers.
  • Patient selection: Best suited for tumors ≤3 cm, non-ptotic breasts, and patients who are not excessively large-breasted.
  • Cost: Requires specialized equipment (CO2 insufflator, 5mm ports, ultrasonic dissectors, possibly robotic platform).
  • Long-term oncologic data: Still maturing; most studies have follow-up of 1-3 years. Multicenter prospective RCTs are lacking.

Summary of Evidence Strength

DomainEvidenceQuality
Cosmesis / patient satisfactionConsistently superior (98% satisfaction; OR 1.88 for cosmetic satisfaction)Moderate (comparative cohorts + meta-analysis)
Oncologic safety (margin rate)Non-inferior (4% positive margins, within open BCS range)Moderate
Local recurrenceComparable (1.3% in multicenter series)Low-moderate (limited follow-up)
Psychological/QoLSignificantly improved (BREAST-Q)Moderate
Radiotherapy toleranceImprovedLow (single study)
SLNB feasibilityDemonstratedLow (case series)
Key citations for your justification:
  1. Xie et al. 2022 - World J Surg Oncol - comparative cohort, n=180, BREAST-Q outcomes
  2. Wang et al. 2024 - Systematic Review (PMID 39013811) - systematic review of endoscopic BCS development
  3. Mathan et al. 2026 - BMC Surg (PMID 41814250) - feasibility with simultaneous SLNB
  4. Choi et al. 2025 - Surg Endosc (PMID 40789780) - first multicenter robot-assisted BCS study (7 centers, n=150)
  5. Huang et al. 2026 - J Robot Surg (PMID 42126517) - robotic vs endoscopic BCS, n=132
  6. Carroll et al. 2025 meta-analysis - PMC12090896 - OR 1.88 for cosmetic satisfaction
  7. Farmah et al. 2025 - ALES narrative review - comprehensive minimally invasive breast surgery review
This is a shared conversation. Sign in to Orris to start your own chat.